Consensus Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq 03:59:48 2024-06-04 pm EDT Pre-market 08:31:16 am
56.23 USD -9.70% Intraday chart for Viking Therapeutics, Inc. 57.11 +1.57%

Evolution of the average Target Price on Viking Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

484737986fb7d85608.8Vg7wMXuG6ObOjuFO2cx6Hq_TUaqLjJoIRP7Al6V48E.wx90iICnWMrYc069Tj5ngRzIBhPhSkIvFGqBe2bXjIC2E3axlboqz8hReg~d97e10625257d7fce36421d626f3ee0a
Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform MT
Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing MT
Viking Therapeutics Insider Sold Shares Worth $22,136,474, According to a Recent SEC Filing MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $138 From $116, Maintains Outperform Rating MT
Stifel Adjusts Viking Therapeutics Price Target to $95 From $80, Maintains Buy Rating MT
BTIG Raises Price Target on Viking Therapeutics to $100 From $86, Keeps Buy Rating MT
Jefferies Starts Viking Therapeutics With Buy Rating, $110 Price Target MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $116 From $46, Maintains Outperform Rating MT
HC Wainwright Raises Price Target on Viking Therapeutics to $90 From $33, Keeps Buy Rating MT
Stifel Adjusts Price Target on Viking Therapeutics to $35 From $30, Maintains Buy Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $46 From $40, Maintains Outperform Rating MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup DJ
Raymond James Adjusts Viking Therapeutics Price Target to $37 From $35, Maintains Outperform Rating MT
Stifel Adjusts Viking Therapeutics' Price Target to $30 From $25, Keeps Buy Rating MT
BTIG Adjusts Viking Therapeutics' Price Target to $36 From $31, Keeps Buy Rating MT
Roth MKM Adjusts Price Target on Viking Therapeutics to $24 From $19, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Viking Therapeutics to $33 From $21, Maintains Buy Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $35 From $30, Maintains Outperform Rating MT
BTIG Research Adjusts Viking Therapeutics Price Target to $31 From $20, Maintains Buy Rating MT
Raymond James Adjusts Viking Therapeutics Price Target to $35 From $12, Maintains Outperform Rating MT
Stifel Nicolaus Adjusts Viking Therapeutics Price Target to $25 From $22, Maintains Buy Rating MT
Stifel Initiates Viking Therapeutics at Buy With $22 Price Target MT
Raymond James Adjusts Price Target on Viking Therapeutics to $12 From $11, Maintains Outperform Rating MT
Oppenheimer Adjusts Viking Therapeutics' Price Target to $17 From $15, Maintains Outperform Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $15 From $13, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
56.23 USD
Average target price
112.7 USD
Spread / Average Target
+100.47%
High Price Target
138 USD
Spread / Highest target
+145.42%
Low Price Target
90 USD
Spread / Lowest Target
+60.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viking Therapeutics, Inc.

Raymond James
Oppenheimer
Stifel Nicolaus
BTIG
Jefferies & Co.
HC Wainwright
Roth MKM
Maxim
SVB Leerink
Vining Sparks
  1. Stock Market
  2. Equities
  3. VKTX Stock
  4. Consensus Viking Therapeutics, Inc.